8-K: Corcept Therapeutics' Phase 3 ROSELLA Trial Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics announces positive Phase 3 ROSELLA trial results for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, demonstrating improved progression-free survival.

Summary

• Corcept Therapeutics' Phase 3 ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint.
• The trial demonstrated a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008).
• Median progression-free survival (PFS-BICR) was 6.5 months for the relacorilant combination, compared to 5.5 months for nab-paclitaxel alone.
• An interim evaluation of overall survival (OS) showed a significant improvement, with a median OS of 16.0 months for the combination versus 11.5 months for nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.012).
• Relacorilant was well-tolerated, with no new safety signals observed.
• The company plans to submit a New Drug Application (NDA) in the United States in the third quarter of 2025 and a Marketing Authorization Application (MAA) in Europe shortly thereafter.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results, suggesting a significant advancement in the treatment of a challenging disease. The planned regulatory submissions further contribute to a positive outlook for the company.

Positives

• The ROSELLA trial achieved its primary endpoint, demonstrating the efficacy of relacorilant in treating platinum-resistant ovarian cancer.
• The combination therapy showed a statistically significant improvement in both progression-free survival and overall survival.
• Relacorilant was well-tolerated, suggesting a favorable safety profile.
• The results support the potential for relacorilant to become a new standard of care for this patient population.
• The company is moving forward with regulatory submissions in both the United States and Europe.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks and uncertainties are detailed in Corcept's SEC filings.
• The success of regulatory submissions (NDA and MAA) is not guaranteed.
• The acceptance and use of relacorilant by physicians and patients are subject to market dynamics and competition.

Future Outlook

Corcept expects to submit its NDA in the U.S. in the third quarter of 2025 and its MAA in Europe shortly thereafter. The company anticipates presenting the full results of the ROSELLA trial at a medical conference this year.

Management Comments

• Alexander B. Olawaiye, M.D., stated that the ROSELLA results represent an important advancement in the development of a treatment for patients with platinum-resistant ovarian cancer.
• Domenica Lorusso, M.D., Ph.D., said that relacorilant in combination with nab-paclitaxel has the potential to become a key strategy to help improve patient outcomes.
• Bill Guyer, PharmD, stated that the improvement in survival seen in ROSELLA, without an increased safety burden, brings the company closer to delivering a new standard-of-care treatment.

Industry Context

The announcement addresses a significant unmet need in the treatment of platinum-resistant ovarian cancer, where limited treatment options exist. The positive results position Corcept to potentially compete with existing therapies and establish a new standard of care.

Comparison to Industry Standards

• The median overall survival of approximately 12 months with single-agent chemotherapy for platinum-resistant ovarian cancer serves as a benchmark.
• The ROSELLA trial's median OS of 16.0 months for the relacorilant combination represents a notable improvement compared to this standard.
• Comparable companies in the ovarian cancer treatment space include those developing PARP inhibitors and other chemotherapeutic agents.
• The trial's design and endpoints align with industry standards for evaluating new cancer therapies.

Stakeholder Impact

• Shareholders may react positively to the news of successful trial results and planned regulatory submissions.
• Patients with platinum-resistant ovarian cancer may benefit from a new treatment option.
• The company's employees may experience increased job security and opportunities for growth.
• The GOG Foundation, ENGOT, APGOT, LACOG and ANZGOG, as collaborators in the ROSELLA trial, may benefit from the advancement of ovarian cancer treatment.

Next Steps

• Corcept plans to present the full results of the ROSELLA trial at a medical conference.
• The company expects to submit an NDA to the FDA in the third quarter of 2025.
• Corcept plans to submit an MAA to the European Medicines Agency (EMA) shortly after the NDA submission.

Key Dates

Keywords

relacorilant, ovarian cancer, platinum-resistant, ROSELLA trial, nab-paclitaxel, progression-free survival, overall survival, Corcept Therapeutics, oncology, NDA, MAA